Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
June 07 2023 - 9:00AM
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical
company developing novel therapeutics targeting dysfunctional
metabolic pathways, today announced that it will present interim
data from the FASCINATE-2 Phase 2b clinical trial of its lead
product candidate, denifanstat, a fatty acid synthase (FASN)
inhibitor, in nonalcoholic steatohepatitis (NASH) at the European
Association for the Study of the Liver (EASL) Congress. The event
will be held in Vienna, Austria from June 21-24, 2023.
Details of the presentation are as follows:
Abstract Title: Multicenter, randomized,
double-blind, placebo-controlled trial of Fatty Acid Synthase
(FASN) inhibitor, denifanstat, versus placebo in the treatment of
biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2
Phase 2b trial.Abstract Number:
1300Presenter: Rohit Loomba, MD,
MHScType: Oral presentationSession
Title: NAFLD: TherapySession Date:
Friday, June 23, 2023 Session Time: 8:30 a.m. CEST
(2:30 a.m. ET)
For more information regarding EASL Congress 2023, please visit
https://easl.eu/event/easl-congress-2023/.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing
novel therapeutics targeting dysfunctional metabolic pathways in
diseases such as NASH, certain cancers and acne. Sagimet compounds
are designed to inhibit FASN, an enzyme involved in the production
of fatty acids normally used for energy storage. In NASH, the
activity of FASN enzyme is upregulated, resulting in excess
accumulation of liver fat, inflammation and fibrosis. Sagimet’s
lead product candidate, denifanstat, an oral, once-daily pill, is
currently being tested in FASCINATE-2, a Phase 2b clinical trial in
NASH with liver biopsy as the primary endpoint. In June 2020,
Sagimet announced positive results from FASCINATE-1, its Phase 2
clinical trial for denifanstat. The results of the Phase 2 clinical
trial were published in
Gastroenterology, the official
journal of the American Gastroenterological Association. For
additional information about Sagimet Biosciences, please visit
www.sagimet.com.
Contact:
Robert UhlManaging Director, ICR
Westwicke858.356.5932robert.uhl@westwicke.com
Sagiment Biosciences (NASDAQ:SGMT)
Historical Stock Chart
From May 2024 to Jun 2024
Sagiment Biosciences (NASDAQ:SGMT)
Historical Stock Chart
From Jun 2023 to Jun 2024